Key points are not available for this paper at this time.
Radiotherapy plus camrelizumab had manageable toxicity and antitumor efficacy for locally advanced ESCC. Several biomarkers were associated with clinical benefit and deserve further study.
Zhang et al. (Sat,) studied this question.